Rachael Brake
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Rachael Brake
Corbus Pharmaceuticals Holdings, Inc. reported in an 8-K filed February 6, 2024 that Rachael Brake resigned as Chief Scientific Officer, effective February 19, 2024. The proxy statement of Corbus Pharmaceuticals Holdings, Inc. reports total compensation of $839,867 for Rachael Brake in fiscal 2023, including a base salary of $453,980. Disclosed compensation is on record for 3 fiscal years.
“On February 2, 2024, Rachael Brake, Ph.D., Chief Scientific Officer of Corbus Pharmaceuticals Holdings, Inc. (the "Company"), submitted a notice of resignation to the Company. The effective date of Dr. Brake's resignation will be February 19, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Proxy statement
Start not stated–2024-04-02
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Chief Scientific Officer | $453,980 | $839,867 |
| 2022 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Chief Scientific Officer | $427,779 | $763,795 |
| 2021 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Chief Scientific Officer | $15,769 | $15,807 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.